First-line therapy in atypical hemolytic uremic syndrome: consideration on infants with a poor prognosis

BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is a rare and heterogeneous disorder. The first line treatment of aHUS is plasma therapy, but in the past few years, the recommendations have changed greatly with the advent of eculizumab, a humanized monoclonal anti C5-antibody. Although recent...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ital J Pediatr
Autors principals: Szarvas, Nóra, Szilágyi, Ágnes, Tasic, Velibor, Nushi-Stavileci, Valbona, Sofijanova, Aspazija, Gucev, Zoran, Szabó, Miklós, Szabó, Attila, Szeifert, Lilla, Reusz, György, Rusai, Krisztina, Arbeiter, Klaus, Müller, Thomas, Prohászka, Zoltán
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2014
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4295478/
https://ncbi.nlm.nih.gov/pubmed/25496981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13052-014-0101-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars